CVRx (CVRX) shares fell 25% in regular trading to $1.98, with volume at nearly 2 million shares, after a major shareholder called on the board to pursue an immediate sale process, raising fresh questions about the company's strategic direction.
What happened
On August 24, 2026, Jorey Chernett, who disclosed ownership of more than 5.5% of CVRx outstanding shares, released a public letter calling on the board to begin an immediate process to pursue a sale of the company to a strategic acquirer. CVRx responded the following day via GlobeNewsWire, stating the board would review and evaluate the proposal. No definitive terms or timeline have been disclosed, leaving investors to weigh the uncertainty of whether a deal will materialize or what price would satisfy the board.
Why the stock moved
Chernett's demand introduced significant uncertainty around CVRx's standalone growth trajectory. The letter, reported by PRNewsWire on August 24, 2026, reflects frustration from a minority shareholder over the company's performance as a public entity. The lack of a board endorsement or rejection of the offer means investors cannot price in a transaction premium with confidence. The HFSA Annual Scientific Meeting data announcement on September 29, 2026, provided clinical updates on Barostim but did not reverse the sentiment shift driven by the buyout pressure.
The numbers
CVRX fell 25% during the session, dropping from a prior close of $2.64 to a last price of $1.98. Volume reached 1,996,157 shares, more than triple the average daily volume of approximately 631,100 shares, indicating heavy liquidation. The company's market capitalization now sits around $52.5 million, with a float of roughly 18.4 million shares. Short interest represents about 2.6 days of average trading volume.
What to watch
Investors should monitor for any formal response from the CVRx board regarding Chernett's proposal. Any indication of board engagement with strategic alternatives could swing the stock. Additionally, upcoming earnings reports and Barostim coverage expansion decisions from Medicare Advantage payers will determine whether the company can deliver standalone value that matches or exceeds a potential buyout offer.